Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-fluoro-2-methyl-n-(4-(5h-pyrrolo(2,1-c)-(1,4)benzodiazepin-10-(11h)-ylcarbonyl)-3-chlorophenyl)benzamide
2. Crtx 080
3. Crtx-080
4. Crtx080
5. N-4-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methylbenzamide
6. Vpa 985
7. Vpa-985
8. Way Vpa-985
9. Way-vpa-985
1. 168079-32-1
2. Vpa-985
3. Way-vpa-985
4. Lixar
5. Vpa 985
6. N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
7. Crtx-080
8. Vpa985
9. Chembl49429
10. Crtx 080
11. 8f5x4b082e
12. Lixivaptan [usan:inn]
13. 3'-chloro-5-fluoro-4'-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)-o-toluanilide
14. Benzamide, N-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methyl-
15. Benzamide, N-[3-chloro-4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbonyl)phenyl]-5-fluoro-2-methyl-
16. N-(3-chloro-4-(10,11-dihydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyl)phenyl)-5-fluoro-2-methylbenzamide
17. Lixivaptan (usan/inn)
18. Way Vpa-985
19. Way-vpa 985
20. Unii-8f5x4b082e
21. Lixivaptan [usan]
22. Lixivaptan [mi]
23. Lixivaptan [inn]
24. Lixivaptan (vpa-985)
25. Lixivaptan [vandf]
26. Lixivaptan [mart.]
27. Lixivaptan [who-dd]
28. Gtpl2238
29. Schembl1649340
30. Dtxsid00168472
31. Hms3747a19
32. Zinc600399
33. Bcp09167
34. Ex-a1129
35. Vpa-985;way-vpa 985
36. Bdbm50065115
37. Mfcd00937905
38. Akos022181388
39. Cs-7512
40. Db06666
41. Ncgc00485402-01
42. Ac-26832
43. Bs-15602
44. Hy-14185
45. Db-064673
46. Ft-0670828
47. D04752
48. L001508
49. 2-chloro-6,7,8,9-tetrahydrobenzocyclohepten-5-one
50. Q6659958
51. 3-chloro-4-(10,11-dihydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-ylcarbonyl)-1-(5-fluoro-2-methylphenylcarboxamido)benzene
52. 5-fluoro-2-methyl-n-(4-(5h-pyrrolo(2,1-c)-(1,4)benzodiazepin-10-(11h)-ylcarbonyl)-3-chlorophenyl)benzamide
53. Benzamide, N-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methyl-;
54. N-[4-(5h,11h-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyl)-3-chloro-phenyl]-5-fluoro-2-methyl-benzamide
55. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbony)-3-chlorophenyl]-5-fluoro-2-methylbenzamide
56. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methyl-benzamide
57. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide
58. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide
59. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin10(11h)-ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide
60. N-4-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methylbenzamide
| Molecular Weight | 473.9 g/mol |
|---|---|
| Molecular Formula | C27H21ClFN3O2 |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 473.1306328 g/mol |
| Monoisotopic Mass | 473.1306328 g/mol |
| Topological Polar Surface Area | 54.3 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 753 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in hyponatremia and congestive heart failure.
Treatment of hyponatraemia
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Lixivaptan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lixivaptan, including repackagers and relabelers. The FDA regulates Lixivaptan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lixivaptan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lixivaptan supplier is an individual or a company that provides Lixivaptan active pharmaceutical ingredient (API) or Lixivaptan finished formulations upon request. The Lixivaptan suppliers may include Lixivaptan API manufacturers, exporters, distributors and traders.
click here to find a list of Lixivaptan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lixivaptan DMF (Drug Master File) is a document detailing the whole manufacturing process of Lixivaptan active pharmaceutical ingredient (API) in detail. Different forms of Lixivaptan DMFs exist exist since differing nations have different regulations, such as Lixivaptan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lixivaptan DMF submitted to regulatory agencies in the US is known as a USDMF. Lixivaptan USDMF includes data on Lixivaptan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lixivaptan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lixivaptan suppliers with USDMF on PharmaCompass.
Lixivaptan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lixivaptan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lixivaptan GMP manufacturer or Lixivaptan GMP API supplier for your needs.
A Lixivaptan CoA (Certificate of Analysis) is a formal document that attests to Lixivaptan's compliance with Lixivaptan specifications and serves as a tool for batch-level quality control.
Lixivaptan CoA mostly includes findings from lab analyses of a specific batch. For each Lixivaptan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lixivaptan may be tested according to a variety of international standards, such as European Pharmacopoeia (Lixivaptan EP), Lixivaptan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lixivaptan USP).
LOOKING FOR A SUPPLIER?
